The Department of Health and Human Services today delayed until July 1, 2019 implementation of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. "With skyrocketing prescription drug price increases presenting hospitals, health systems and patients with remarkable challenges, the 340B program is as critical as ever in helping provide access to health care services for vulnerable patients and communities,” said AHA Executive Vice President Tom Nickels. “The 340B ceiling price and civil monetary penalties rule were intended to shine needed light on drug manufacturer price increases and hold drug manufacturers accountable for price overcharging. These reasons are why we continue to be disappointed in the delays – including five times since the beginning of last year alone – of the final rule and in the short shrift given to the review of the latest public comments. The irony is not lost on us that drug manufacturers continue to lobby for increased reporting for hospitals and others while refusing any transparency on their part."

Related News Articles

Headline
The American Society for Health Care Engineering July 1 announced 87 health care facilities as winners of the 2025 Energy to Care Sustainability Champions…
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…
Headline
The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the state’s 340B contract pharmacy law…
Chairperson's File
Public
Advocacy is a core part of the work of the AHA, protecting and sustaining what hospitals and health systems need to truly care for our communities. We often…
Headline
A U.S. District Court for the District of Columbia judge June 27 ruled against Johnson & Johnson and sided with the Department of Health and Human Services…
Headline
The AHA June 16 released a report showing hospitals that participated in the 340B Drug Pricing Program are not only subject to disproportionately greater…